Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 13, 2016 7:09 AM ET

Pharmaceuticals

Company Overview of Claris Lifesciences Limited

Company Overview

Claris Lifesciences Limited, together with its subsidiaries, manufactures and sells drugs and pharmaceuticals worldwide. The company manufactures and markets products for anesthesia and analgesia, blood products, plasma volume expanders, anti-infectives, and oncology segments. It also provides dialysis and transplant range across systems, solutions, medicines, disposables, and equipment. In addition, the company offers injectables for various therapeutic groups, including anti-emetics, CNS, cardiology, anti-malaria, haematinics, etc. It offers its products through various delivery systems, such as glass and plastic bottles, ampoules, and non-PVC/PVC bags. The company primarily serves governm...

Near Parimal Railways Crossing

Ellisbridge

Ahmedabad,  380006

India

Founded in 1994

1,092 Employees

Phone:

91 79 2656 3331

Fax:

91 79 2640 8053

Key Executives for Claris Lifesciences Limited

Vice Chairman, Managing Director, Member of Share Transfer Committee, Member of Executive Committee, Member of Corporate Social Responsibility Committee and Member of Stakeholders Relationship Committee
Age: 35
Total Annual Compensation: $26.5M
Chief Financial Officer, Whole Time Director, Member of Share Transfer Committee, Member of Executive Committee, Member of Audit Committee, Member of Corporate Social Responsibility Committee and Member of Stakeholders Relationship Committee
Age: 41
Total Annual Compensation: $9.4M
Compliance Officer, Senior Vice President and Company Secretary
Total Annual Compensation: $6.7M
Whole Time Director, Member of Share Transfer Committee, Member of Executive Committee and Member of Corporate Social Responsibility Committee
Age: 62
Total Annual Compensation: $5.8M
Compensation as of Fiscal Year 2015.

Claris Lifesciences Limited Key Developments

Claris Lifesciences Limited Reports Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2015

Claris Lifesciences Limited reported audited consolidated and standalone earnings results for the third quarter and nine months ended December 31, 2015. For the quarter, on consolidated basis, net sales /income from operations was INR 1,920.731 million compared to INR 1,791.481 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 171.7881 million compared to INR 376.147 million a year ago. Profit from ordinary activities before tax was INR 248.252 million against INR 530.284 million a year ago. Net profit was INR 158.984 million compared to INR 902.987 million a year ago. Net loss per basic and diluted share before and after extraordinary items was INR 12.62 per compared to net income per basic and diluted share before and after extraordinary items of INR 16.47 a year ago. EBITDA was INR 460 million compared to INR 470 million a year ago. For the nine months, on consolidated basis, net sales /income from operations was INR 5,721.061 million compared to INR 4,922.933 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 858.371 million compared to INR 829.733 million a year ago. Profit from ordinary activities before tax was INR 870.515 million against INR 1,073.181 million a year ago. Net profit was INR 271.463 million compared to INR 1,287.576 million a year ago. Net loss per diluted share before and after extraordinary items was INR 4.36 per compared to net income per basic and diluted share before and after extraordinary items of INR 22.13 a year ago. For the quarter, on standalone basis, net sales /income from operations was INR 1,437.143 million compared to INR 1,580.450 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 1.781 million compared to INR 170.241 million a year ago. Profit from ordinary activities before tax was INR 110.967 million against INR 332.715 million a year ago. Net profit was INR 80.329 million or INR 1.47 per basic and diluted share before and after extraordinary items compared to INR 836.776 million or INR 15.33 per basic and diluted share before and after extraordinary items a year ago. For the nine months, on standalone basis, net sales /income from operations was INR 4,223.985 million compared to INR 4,464.895 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 38.331 million compared to INR 599.361 million a year ago. Profit from ordinary activities before tax was INR 341.574 million against INR 826.654 million a year ago. Net loss was INR 96.138 million or INR 1.76 per diluted share before and after extraordinary items compared to net profit of INR 1,182.744 million or INR 20.83 per basic and diluted share before and after extraordinary items a year ago.

Claris Lifesciences Limited, Board Meeting, Feb 05, 2016

Claris Lifesciences Limited, Board Meeting, Feb 05, 2016. Agenda: To consider quarterly results; to comply with the regulations of the Companies Act, 2013 by replacing existing set of articles of association of the company with a new set of articles of association to amend it in accordance with the Companies Act, 2013; and to continue complying with requirements of Section 186, to take approval for limits for giving loans/to give guarantees/providing securities/ making investments by the company not exceeding INR 15,000 million over and above the limits prescribed under Sections 186(2) of the Companies Act, 2013 and rules thereunder.

Claris Lifesciences Reported Re-Starts Talks For Sale Of Injectable Business

Claris Lifesciences Limited (BSE:533288) has again started discussions regarding deal talks to sell its injectable business, three independent sources with direct knowledge of the deal said. Sources stated that Claris expects the valuations of the injectables business at over INR 30 billion. Sources suggest that Claris Lifesciences has sent feelers to prospective buyers and it has received interest from companies like Torrent Pharmaceuticals Ltd. (BSE:500420), Dr. Reddy's Laboratories Ltd. (BSE:500124), Claris Lifesciences Limited (BSE:533288) amongst others. Cadila Healthcare had reached the advanced stage, a source said. Claris Lifesciences spokesperson denied deal talks.

Similar Private Companies By Industry

Company Name Region
Agrata Biotech Limited Asia
Avery Bio-tech Private Limited Asia
Sri Krishna Pharmaceuticals Limited Asia
Phloem Pharma Pvt. Ltd. Asia
Windlas Biotech Limited Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Claris Lifesciences Limited, please visit www.clarislifesciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.